Swiss National Bank
SYRE icon

Swiss National Bank’s Spyre Therapeutics SYRE Stock Holding History

Swiss National Bank’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99M Buy
112,500
+16,000
+17% +$1.17M 0.01% 1020
2026
Q1 		$4.87M Hold
96,500
– – ﹤0.01% 1384
2025
Q4 		$3.16M Buy
96,500
+26,300
+37% +$687K ﹤0.01% 1625
2025
Q3 		$1.18M Buy
70,200
+1,600
+2% +$26.1K ﹤0.01% 2098
2025
Q2 		$1.03M Hold
68,600
– – ﹤0.01% 2127
2025
Q1 		$1.11M Hold
68,600
– – ﹤0.01% 2085
2024
Q4 		$1.6M Buy
68,600
+19,000
+38% +$557K ﹤0.01% 1977
2024
Q3 		$1.46M Buy
49,600
+13,500
+37% +$376K ﹤0.01% 2033
2024
Q2 		$849K Sell
36,100
-3,000
-8% -$101K ﹤0.01% 2245
2024
Q1 		$1.48M Buy
+39,100
New +$1.13M ﹤0.01% 2002

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Swiss National Bank's SYRE Position: Q2 2026 in Review

Swiss National Bank increased its Spyre Therapeutics (SYRE) stake by 17% in Q2 2026, buying an estimated $1.17M and bringing the position to 112,500 shares worth $9.99M. The position accounts for 0.01% of the portfolio, ranked #1020.

Swiss National Bank first reported a position in SYRE in Q1 2024 and has held it in 10 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Swiss National Bank held 112,500 shares of Spyre Therapeutics worth $9.99M as of Q2 2026.
  • Swiss National Bank bought 16,000 Spyre Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Spyre Therapeutics made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #1020 holding.
  • Swiss National Bank first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.